Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for prostate cancer: an update.

Richard J Bryant1, Freddie C Hamdy

  • 1Academic Urology Unit, Section of Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom.

European Urology
|September 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Prostate Score for Identifying Biologically Low-risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy.

European urology oncology·2026
Same author

3D pathology-guided microdissection.

Nature methods·2026
Same author

Radical Prostatectomy in Low-volume Metastatic Prostate Cancer? The Need for New Evidence.

European urology·2026
Same author

Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy.

BJU international·2026
Same author

An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study.

NPJ digital medicine·2026
Same author

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

BJU international·2026
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Prostate cancer screening programs are not recommended due to insufficient evidence and concerns about overtreating indolent disease. Future clinical trials may provide data to inform practice and improve patient outcomes.

Area of Science:

  • Urology
  • Oncology
  • Public Health Policy

Background:

  • Prostate cancer screening remains a contentious issue in urological practice.
  • The evidence base for widespread prostate cancer screening is currently insufficient.
  • Concerns exist regarding the overtreatment of indolent prostate cancer detected through screening.

Purpose of the Study:

  • To review evidence on prostate cancer screening programs.
  • To highlight challenges in managing screen-detected prostate cancer.

Main Methods:

  • Systematic literature review using PubMed database.
  • Examination of the evidence base for prostate cancer screening.

Main Results:

  • Current evidence does not support prostate cancer screening as a public health policy.

Related Experiment Videos

  • The natural history of screen-detected prostate cancer is poorly understood.
  • Screening may lead to the detection and overtreatment of indolent disease.

    • Conclusions:

    • National screening programs are not implemented due to a lack of evidence for improved survival or quality of life.
    • Upcoming clinical trials and risk stratification may alter future screening practices.
    • Preventing overtreatment of indolent prostate cancer is a key future consideration.